Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Therapeutic
- Cancer
- Disease
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2917
License Grant
Licensor grants to the Licensee of Germany an exclusive, even as to Licensor, worldwide license, including the right to sublicense through multiple tiers of sublicense, under the Licensor Technology and Licensor’s interest in the Joint Patents, in each case solely to develop, make, have made, use, sell, have sold, offer for sale and import Products in the Field during the Term.
License Property
Licensor has acquired and developed expertise and proprietary rights related to compounds that inhibit the biological target known as MEK.
MEK shall mean mitogen-activated erk kinase.
Product shall mean a Preclinical Product, a RDEA119 Product or a RDEA436 Product.
RDEA119 Product shall mean any pharmaceutical product containing or comprising the Licensed Compound referred to as RDEA119.
RDEA436 Product shall mean any pharmaceutical product containing or comprising the Licensed Compound referred to as RDEA436.
Patents include
– Derivatives of N-(Arylamino) Sulfonamides as Inhibitors of MEK;
– Polymorphic Form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodopheny )amino )-6-methoxyphenyl )-1-(2,3-dihydroxypropy I) cyclopropane-1-sulfonamide and Uses Thereof;
– Compositions and Methods for Preparing and Using Same;
– Method of Treating Pancreatic Cancer;
– Pharmaceutical Combinations for Treatment of Specific Cancers;
– Pyridone Sulfonamides and Pyridone Sulfamides as MEK Inhibitors;
– Inhibitors of MEK;
– Carboxamidines; and,
– N-Aryl-N'Alkyl Sulfamides as MEK Inhibitors.
RDEA119 is currently being evaluated both as a single agent and in combination with sorafenib in advanced cancer patients.
Derivatives ofN-(Arylamino) Sulfonamides as Inhibitors ofMEK
App. No. 11/830,733
Field of Use
The Licensor entered into the License Agreement with the Licensee to develop and commercialize small-molecule mitogen-activated ERK kinase inhibitors for the treatment of cancer.
IPSCIO Record ID: 2909
License Grant
The Licensee acquired intellectual property and other assets from the Licensor related to RDEA806 and our next generation NNRTI program, and RDEA119 and our next generation MEK inhibitor program.
Field of Use
The Licensee agreed to further develop these compounds with the objective of obtaining marketing approval in the United States, the United Kingdom, France, Spain, Italy and Germany.
IPSCIO Record ID: 135967
License Grant
This amendment includes commercialization rights for cabozantinib in Canada.
License Property
Cobimetinib is a potent, highly selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. This pathway mediates signaling downstream of growth factor receptors, and is prominently activated in a wide variety of human tumors. It is indicated in combination with vemurafenib as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. The company is a biopharmaceutical company that discovers, develops and commercializes small molecule therapies for the treatment of cancer. The business focuses predominantly on the development and commercialization of cabozantinib, an internally-discovered inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is currently approved in the United States and European Union for the treatment of progressive, metastatic medullary thyroid cancer, or MTC, and is marketed under the brand name COMETRIQ®.
Field of Use
The Company is developing its proprietary compound known as cabozantinib for the treatment of cancer, and owns or controls certain patents, know-how and other intellectual property relating to such compound.
IPSCIO Record ID: 61018
License Grant
The Company hereby grants to French Licensee, during the Term
(a) an exclusive royalty-bearing license, with the right to grant sublicenses solely as provided under the Company Technology to use, sell, offer for sale, import and otherwise Commercialize (but not to make or have made) the Products in the Field and in the Licensee Territory; and
(b) a non-exclusive license, with the right to grant sublicenses solely as provided under the Company Technology to Develop (but not to make or have made) the Products on a worldwide basis under the GDP, and to use the Products for that purpose. Exelixis agrees not to grant any further license to Develop the Products except to Future Exelixis Licensees.
License Property
The Company is developing its proprietary compound known as cabozantinib for the treatment of cancer, and owns or controls certain patents, know-how and other intellectual property relating to such compound.
Cobimetinib is a potent, highly selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. This pathway mediates signaling downstream of growth factor receptors, and is prominently activated in a wide variety of human tumors. It is indicated in combination with vemurafenib as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. The company is a biopharmaceutical company that discovers, develops and commercializes small molecule therapies for the treatment of cancer. The business focuses predominantly on the development and commercialization of cabozantinib, an internally-discovered inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is currently approved in the United States and European Union for the treatment of progressive, metastatic medullary thyroid cancer, or MTC, and is marketed under the brand name COMETRIQ®.
Field of Use
The agreement pertains to the drug industry.
IPSCIO Record ID: 27879
License Grant
Licensors hereby grant to Licensee an exclusive, worldwide license, including the right to sublicense, under Licensor Patent Rights and Future Patent Rights, to make, have made, use, sell, import and export Products.
License Property
Methods for Therapy Sensitization by Inhibition of Jun Kinase Patent Attorney Docket No. P-UR 2590 (2841302).
Field of Use
The term Field shall mean methods for therapy sensitization by the inhibition of jun kinase and/or the claims specified in the patent application.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
